{
  "schemaVersion": 2,
  "eyebrow": "Neurocritical Care",
  "title": "Myasthenic Crisis Treatment Selection",
  "summary": "Select plasma exchange or IVIG immediately for crisis or imminent respiratory and bulbar failure, while securing the airway, treating precipitants, and sequencing corticosteroids to avoid early worsening. Choice depends on physiologic urgency, access, contraindications, prior response, and complications.",
  "seoDescription": "Physician guide to selecting plasma exchange, IVIG, corticosteroids, ventilation, and escalation strategies for myasthenic crisis.",
  "clinicalQuestion": "How should clinicians select and sequence rescue immunotherapy, ventilatory support, and corticosteroids in myasthenic crisis?",
  "specialty": "Neurology and Critical Care Medicine",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "myasthenic crisis",
    "plasma exchange",
    "PLEX",
    "IVIG",
    "myasthenia gravis",
    "respiratory failure",
    "neurocritical care"
  ],
  "keyTakeaways": [
    "Admit impending crisis for close respiratory and bulbar observation; manage manifest crisis in an ICU or step-down setting capable of airway and ventilatory support. [20]",
    "Use PLEX or IVIG as short-term rescue therapy for impending or manifest crisis and for significant respiratory or bulbar dysfunction; both are crisis mainstays. [20][22]",
    "Prefer PLEX when the need for a rapid, pronounced response is greatest and vascular access and hemodynamic tolerance permit; several studies suggest faster clinical improvement than IVIG. [19][23]",
    "Use IVIG when PLEX is impractical or poorly tolerated; IVIG and PLEX have comparable efficacy for moderate-to-severe generalized exacerbations, although comparative crisis data are mixed. [6][11][23]",
    "Start or adjust sustained immunosuppression, usually corticosteroids, but consider waiting several days after PLEX or IVIG begins because corticosteroids can transiently worsen weakness. [20]",
    "Avoid assuming that ocular-predominant immune checkpoint inhibitor-associated MG is benign: rapid deterioration can occur, and early IVIG or PLEX is favored over corticosteroids alone. [3]"
  ],
  "sections": [
    {
      "id": "triage-airway-and-level-of-care",
      "eyebrow": "First Decision",
      "heading": "Separate impending crisis from manifest crisis before choosing rescue therapy",
      "intro": "Treatment selection begins with airway risk and the capacity to rescue deterioration immediately.",
      "paragraphs": [
        "Admit a patient with impending crisis to the hospital for close serial assessment of respiratory and bulbar function, with immediate capability to transfer to intensive care if deterioration occurs. Admit manifest crisis to an ICU or step-down unit able to manage respiratory failure and bulbar dysfunction. [20]",
        "Define the immediate airway problem clinically: respiratory insufficiency requiring mechanical ventilation or intubation for airway protection constitutes myasthenic crisis. Do not defer intubation in progressive ventilatory failure, ineffective airway protection, or rapidly worsening bulbar weakness while waiting for immunotherapy to work. [4][11]",
        "At presentation, actively identify and correct reversible precipitants while initiating rescue treatment. Crisis care priorities include airway, respiratory, and circulatory support; confirmation of MG and crisis; evaluation and treatment of acute respiratory failure; elimination of triggers; immunomodulatory treatment; and prevention or treatment of complications. [11]"
      ],
      "bullets": [
        "Obtain serial bedside respiratory and bulbar assessments in impending crisis; worsening function should trigger ICU transfer rather than outpatient or routine-floor observation. [20]",
        "Assess for excessive acetylcholinesterase inhibitor effect when clinical worsening is unexplained, because cholinesterase inhibitors increase airway secretions and can aggravate breathing difficulty. [20]",
        "Treat PLEX or IVIG as rescue therapy, not as a substitute for airway management; their benefit is rapid relative to chronic immunosuppression but not immediate. [9][23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Level-of-care and rescue-treatment decisions in impending versus manifest myasthenic crisis. [20][22]",
        "columns": [
          "Clinical state",
          "Disposition",
          "Immediate treatment selection",
          "Decision trigger"
        ],
        "rows": [
          [
            "Impending crisis with worsening respiratory or bulbar function",
            "Hospital admission with close observation and capacity for ICU transfer. [20]",
            "Initiate PLEX or IVIG when rapid improvement is needed or respiratory/bulbar dysfunction is significant. [20]",
            "Progression in respiratory or bulbar impairment warrants ICU-level management. [20]"
          ],
          [
            "Manifest crisis with respiratory failure or airway-protection indication",
            "ICU or capable step-down unit. [20]",
            "Provide airway and ventilatory support; initiate PLEX or IVIG as crisis rescue therapy. [20][22]",
            "Mechanical ventilation or intubation for airway protection defines the crisis state. [4]"
          ]
        ]
      }
    },
    {
      "id": "plex-versus-ivig",
      "eyebrow": "Rescue Immunotherapy",
      "heading": "Choose PLEX or IVIG according to urgency, feasibility, and patient-specific risk",
      "intro": "Both modalities are accepted short-term therapies; selection should be deliberate rather than protocol automatic.",
      "paragraphs": [
        "PLEX and IVIG are both appropriate short-term treatments for life-threatening respiratory insufficiency or dysphagia, significant bulbar dysfunction before surgery, need for rapid response, inadequate response to other treatments, and selected situations before corticosteroid initiation. [20] PLEX has strong guideline support and typically reaches maximal efficacy after three to five treatment sessions. [1]",
        "When physiologic urgency is extreme, PLEX is commonly favored if it can be delivered safely. Comparative literature describes PLEX as producing faster and more noticeable improvement in some studies, and a retrospective crisis cohort found PLEX superior to IVIG for 7-day severity, 2-week ventilation status, and 1-month functional outcome; these data are not definitive enough to establish universal superiority. [11][19][23]",
        "Choose IVIG when the logistics, vascular access requirements, or hemodynamic demands of PLEX are unfavorable, or when IVIG is the more deliverable option. Randomized studies in MG exacerbation found IVIG as effective as PLEX at approximately 14 to 15 days, and an earlier trial found no difference in myasthenic muscle score at day 15 among PLEX and IVIG regimens. [6][11] In COVID-19-associated crisis, IVIG may be preferable because PLEX removes circulating protective as well as pathogenic antibodies, although the clinical consequence of lowering antiviral antibody titers remains uncertain. [23]",
        "Do not interpret failure of one modality as a reason to abandon rescue therapy. If an exacerbation or crisis was not attributable to primary failure of the initial modality, retreatment may be reasonable; after exposure to both therapies, clinicians may retry the modality associated with the better prior response when there is a plausible benefit. [21]"
      ],
      "bullets": [
        "Favor PLEX when rapid clinical reversal is the dominant need and the patient can undergo exchange safely. [1][19][23]",
        "Favor IVIG when PLEX access or tolerance is limiting, or when infection-related concerns make removal of circulating protective antibodies undesirable. [23]",
        "For preoperative optimization, three plasmapheresis treatments are recommended in one contemporary review. [17]",
        "Do not select efgartigimod, complement inhibition, or other newer targeted agents as routine first-line crisis rescue on the basis of chronic generalized-MG indications; crisis evidence is limited and includes case-based experience for eculizumab after unsuccessful standard rescue treatment. [1][14]"
      ],
      "subsections": [
        {
          "heading": "What the comparative evidence changes",
          "paragraphs": [
            "The evidence supports a modality-selection approach rather than a claim that one rescue therapy always dominates. IVIG and PLEX are generally considered equally effective for moderate-to-severe generalized MG exacerbation with a similar duration of benefit, but PLEX may provide a faster or more pronounced response in severe crisis. [6][19][23] Therefore, use urgency, feasibility, prior response, and complication risk to break the tie."
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Practical selection between plasma exchange and IVIG for acute MG deterioration. [1][6][11][19][20][23]",
        "columns": [
          "Factor",
          "PLEX",
          "IVIG",
          "How it changes selection"
        ],
        "rows": [
          [
            "Need for speed in severe crisis",
            "Often associated with faster and more noticeable improvement; peak effect is typically reached after three to five sessions. [1][19]",
            "Effective rescue therapy but may be selected less often when the fastest response is required. [23]",
            "Favor PLEX when immediate reversal of severe weakness is the priority and delivery is feasible. [19][23]"
          ],
          [
            "Moderate-to-severe exacerbation efficacy",
            "Comparable with IVIG in randomized exacerbation studies at about 14 to 15 days. [6]",
            "Comparable with PLEX in randomized exacerbation studies at about 14 to 15 days. [6]",
            "Either is reasonable when urgency does not clearly favor PLEX. [6][23]"
          ],
          [
            "Respiratory or bulbar dysfunction",
            "Appropriate short-term therapy. [20]",
            "Appropriate short-term therapy. [20]",
            "Do not delay either modality when dysfunction is clinically significant. [20]"
          ],
          [
            "COVID-19-associated crisis",
            "May remove protective as well as pathogenic antibodies. [23]",
            "Often more appropriate in this setting. [23]",
            "Favor IVIG when this immunologic tradeoff is important. [23]"
          ],
          [
            "Preoperative optimization",
            "Three treatments are recommended in one review. [17]",
            "May be used in selected patients, although a trial did not show pre-thymectomy benefit for IVIG. [6]",
            "Consider PLEX for significant preoperative weakness when rapid optimization is needed. [17]"
          ]
        ]
      }
    },
    {
      "id": "corticosteroids-and-cholinesterase-inhibitors",
      "eyebrow": "Treatment Sequencing",
      "heading": "Sequence corticosteroids after rescue therapy when early worsening could endanger the airway",
      "intro": "Rescue immunotherapy provides short-lived benefit; sustained immunosuppression must be timed around its early risks.",
      "paragraphs": [
        "Corticosteroids or other immunosuppressive agents are commonly started at the time of PLEX or IVIG to establish a sustained response. Because corticosteroids can transiently worsen myasthenic weakness, it may be safer to wait several days for PLEX or IVIG benefit before initiating corticosteroids when respiratory or bulbar reserve is limited. [20]",
        "Corticosteroids remain an important component of crisis treatment in most patients, but they do not replace PLEX or IVIG for acute rescue because clinical response requires weeks and maximal benefit is delayed. [8][23] In a patient who is already unstable, use airway planning and rescue immunotherapy to bridge this delay rather than relying on steroid escalation alone. [20][23]",
        "Reassess pyridostigmine and other cholinesterase inhibitors during crisis. Excess cholinesterase inhibition is an uncommon but possible contributor to deterioration, and increased airway secretions can worsen respiratory management. [20] In the intubated patient with secretion burden, this tradeoff may favor withholding or reducing the agent until airway control and respiratory mechanics improve."
      ],
      "bullets": [
        "If starting corticosteroids in a patient with substantial bulbar or respiratory weakness, consider first giving PLEX or IVIG and waiting several days for initial benefit. [20]",
        "Use PLEX or IVIG again when clinical deterioration reflects insufficient short-term response; do not expect corticosteroids alone to reverse acute failure. [20][23]",
        "Investigate worsening after pyridostigmine for secretion-related respiratory compromise and possible excess cholinesterase effect. [20]"
      ],
      "subsections": [],
      "table": {
        "caption": "Sequencing immunotherapy and cholinesterase inhibition during crisis. [8][20][23]",
        "columns": [
          "Intervention",
          "Role in crisis",
          "Timing consideration",
          "Key tradeoff"
        ],
        "rows": [
          [
            "PLEX or IVIG",
            "Primary short-term rescue therapy for impending or manifest crisis. [20][22]",
            "Start promptly when respiratory or bulbar dysfunction is significant. [20]",
            "Benefits are temporary and require a plan for sustained disease control. [23]"
          ],
          [
            "Corticosteroids",
            "Build sustained immunosuppressive response in most patients. [8][20]",
            "May begin with rescue therapy, but waiting several days after PLEX or IVIG is appropriate when transient worsening would be dangerous. [20]",
            "Can transiently exacerbate weakness and may worsen infection. [20][23]"
          ],
          [
            "Cholinesterase inhibitor",
            "May require reassessment during respiratory failure. [20]",
            "Adjust according to airway secretion burden and clinical trajectory. [20]",
            "Increased airway secretions may exacerbate breathing difficulties. [20]"
          ]
        ]
      }
    },
    {
      "id": "ventilation-and-extubation",
      "eyebrow": "Respiratory Support",
      "heading": "Use extubation readiness and pulmonary complications to guide ventilatory strategy",
      "intro": "Successful rescue treatment does not eliminate the need for a cautious liberation plan.",
      "paragraphs": [
        "Mechanical ventilation is indicated for neuromuscular respiratory failure or when intubation is required for airway protection. [4] Continue aggressive respiratory support while PLEX or IVIG takes effect; intubation itself should not be viewed as rescue-treatment failure because crisis is defined by the need for ventilatory support or airway protection. [4][20]",
        "Before extubation, integrate bedside respiratory performance with pulmonary complication status. In a study of myasthenic crisis, male sex, prior crisis, atelectasis, and intubation longer than 10 days were associated with extubation failure. Among patients evaluated for reintubation, lower pH, lower forced vital capacity at extubation, atelectasis, and post-extubation BiPAP use predicted reintubation. [4]",
        "Treat atelectasis and other pulmonary complications before a marginal extubation attempt whenever possible. Noninvasive ventilation may help avoid reintubation in selected patients, but the association between post-extubation BiPAP use and reintubation identifies a high-risk group rather than proof that BiPAP causes failure. [4][17]"
      ],
      "bullets": [
        "Delay extubation when forced vital capacity is declining, acidemia persists, or atelectasis has not been addressed; each was associated with a higher reintubation risk in crisis cohorts. [4]",
        "Anticipate prolonged ventilatory support in patients with prior crisis or intubation exceeding 10 days. [4]",
        "Use noninvasive ventilation selectively after extubation, with close monitoring for fatigue, secretion retention, or recurrent airway-protection failure. [4][17]"
      ],
      "subsections": [],
      "table": {
        "caption": "Factors associated with extubation failure or reintubation in myasthenic crisis. [4]",
        "columns": [
          "Finding",
          "Association",
          "Bedside implication"
        ],
        "rows": [
          [
            "Atelectasis",
            "Associated with extubation failure and reintubation. [4]",
            "Address pulmonary collapse before extubation and monitor closely afterward. [4]"
          ],
          [
            "Intubation longer than 10 days",
            "Associated with extubation failure. [4]",
            "Plan a higher-risk liberation strategy rather than a routine extubation trial. [4]"
          ],
          [
            "Lower pH at extubation",
            "Predicted reintubation in analyzed patients. [4]",
            "Correct or explain acidemia before proceeding with extubation. [4]"
          ],
          [
            "Lower forced vital capacity at extubation",
            "Predicted reintubation. [4]",
            "Use low FVC as a warning against extubating on apparent limb-strength improvement alone. [4]"
          ],
          [
            "BiPAP after extubation",
            "Associated with reintubation. [4]",
            "Treat post-extubation NIV requirement as a marker for intensified surveillance. [4]"
          ]
        ]
      }
    },
    {
      "id": "special-scenarios-and-escalation",
      "eyebrow": "Exceptions",
      "heading": "Escalate early in immune checkpoint inhibitor-associated and refractory crisis",
      "intro": "Etiology and prior rescue response can change the urgency and acceptable treatment sequence.",
      "paragraphs": [
        "Immune checkpoint inhibitor-associated MG can progress rapidly irrespective of initial apparent severity. In a systematic review and single-center series, 14 of 38 patients initially treated with corticosteroids alone progressed to respiratory failure, including four initially presenting with ocular symptoms; 18 of 19 patients receiving IVIG or PLEX first line improved. [3] Hospitalize these patients and use early IVIG or PLEX rather than waiting for steroid response when MG is suspected clinically. [3]",
        "For refractory crisis after standard PLEX or IVIG, do not substitute case-report evidence for established rescue pathways. Eculizumab has been reported in refractory crisis, including successful extubation after failed PLEX and high-dose prednisone, but the evidence base consists of a case report and 19 additional reported cases. [14] If considered, recognize the need for prompt meningococcal vaccination and antibiotic prophylaxis described in that report; this is an exceptional rescue decision rather than routine first-line care. [14]",
        "After acute stabilization, transition to long-term MG management rather than repeating rescue therapy indefinitely. The broader treatment armamentarium includes corticosteroids, nonsteroidal immunosuppressive therapy, FcRn inhibitors, complement inhibitors, B-cell-directed therapy, and thymectomy; thymectomy is required for thymoma and can benefit AChR-antibody-positive generalized nonthymomatous MG. [1][2]"
      ],
      "bullets": [
        "In immune checkpoint inhibitor-associated MG, do not use isolated ocular symptoms to justify outpatient observation or corticosteroids alone. [3]",
        "Consider refractory targeted therapy only after standard rescue approaches have failed or are contraindicated, with infection-prevention requirements explicitly addressed for complement inhibition. [14]",
        "Assess for thymoma as part of definitive MG management; thymoma requires thymectomy. [2]"
      ],
      "subsections": [],
      "table": {
        "caption": "Treatment-selection exceptions that alter the usual crisis pathway. [2][3][14]",
        "columns": [
          "Scenario",
          "Selection change",
          "Evidence-based rationale"
        ],
        "rows": [
          [
            "Immune checkpoint inhibitor-associated MG",
            "Hospitalize and use IVIG or PLEX early rather than corticosteroids alone. [3]",
            "Rapid deterioration occurred despite initially mild presentations; first-line IVIG or PLEX was associated with improvement in 18 of 19 reported patients. [3]"
          ],
          [
            "Refractory crisis after standard rescue",
            "Consider exceptional escalation such as eculizumab only with specialist-led risk assessment. [14]",
            "Published crisis experience is limited to case-based literature; reported use included meningococcal vaccination and antibiotic prophylaxis. [14]"
          ],
          [
            "Thymoma-associated MG after stabilization",
            "Plan thymectomy as definitive disease-directed treatment. [2]",
            "Thymectomy is required when thymoma is present. [2]"
          ]
        ]
      }
    }
  ],
  "faq": [],
  "references": [
    {
      "number": 1,
      "title": "Efgartigimod following plasma exchange in the treatment of subjects ...",
      "detail": "neurologyopen.bmj.com",
      "url": "https://neurologyopen.bmj.com/content/7/2/e001180.full.pdf",
      "authors": "neurologyopen.bmj.com",
      "host": "neurologyopen.bmj.com"
    },
    {
      "number": 2,
      "title": "Myasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/238",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 3,
      "title": "Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer",
      "detail": "jitc.bmj.com",
      "url": "https://jitc.bmj.com/content/7/1/319",
      "authors": "jitc.bmj.com",
      "host": "jitc.bmj.com"
    },
    {
      "number": 4,
      "title": "Predictors of Extubation Failure in Myasthenic Crisis",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/795877",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 5,
      "title": "Noninvasive Ventilation in Myasthenic Crisis - JAMA Network",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/795076",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com"
    },
    {
      "number": 6,
      "title": "Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-020-70539-4",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 7,
      "title": "Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-79918-7",
      "authors": "www.nature.com",
      "host": "www.nature.com"
    },
    {
      "number": 8,
      "title": "Neuromuscular Disorders in the Intensive Care Unit - Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2021/10000/neuromuscular_disorders_in_the_intensive_care_unit.10.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 9,
      "title": "Acute Neuromuscular Respiratory Failure | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2015/10000/acute_neuromuscular_respiratory_failure.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 10,
      "title": "Risk factors of myasthenic crisis after thymectomy for thymoma ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ejcts/article/52/4/692/4036297",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 11,
      "title": "Myasthenic crisis",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27832",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 12,
      "title": "Thymectomy for non-thymomatous myasthenia gravis",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ejcts/article-pdf/37/1/7/17791644/37-1-7.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com"
    },
    {
      "number": 13,
      "title": "Myasthenic crisis: Guidelines for prevention and treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0022510X07003127",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 14,
      "title": "Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S030384672500294X",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 15,
      "title": "Myasthenic crisis: Guidelines for prevention and treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022510X07003127",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 16,
      "title": "Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared to Without Rescue Treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0149291825002188",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com"
    },
    {
      "number": 17,
      "title": "Myasthenic crisis - Claytor - 2023 - Muscle & Nerve",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/mus.27832",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com"
    },
    {
      "number": 18,
      "title": "1670: COMPARATIVE EFFICACY OF IVIG AND PLASMA... - Lippincott",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ccmjournal/fulltext/10.1097/01.ccm.0001188676.64318.06~1670-comparative-efficacy-of-ivig-and-plasma-exchange-in",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 19,
      "title": "Myasthenic crisis : Muscle & Nerve - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/01445484-202307000-00006",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 20,
      "title": "International consensus guidance for management of myasthenia gravis",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000002790",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 21,
      "title": "3 Committee discussion | Rozanolixizumab for treating antibody-positive generalised myasthenia gravis | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ta1155/chapter/3-Committee-discussion",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk"
    },
    {
      "number": 22,
      "title": "International consensus guidance for management of myasthenia ...",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/pdfdirect/10.1212/wnl.0000000000002790",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 23,
      "title": "Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000010651",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    },
    {
      "number": 24,
      "title": "Myasthenia gravis",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/CPJ.0b013e31828d9fec",
      "authors": "www.neurology.org",
      "host": "www.neurology.org"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "Efgartigimod following plasma exchange in the treatment of subjects ...",
      "detail": "neurologyopen.bmj.com",
      "url": "https://neurologyopen.bmj.com/content/7/2/e001180.full.pdf",
      "authors": "neurologyopen.bmj.com",
      "host": "neurologyopen.bmj.com",
      "snippet": "during life-­ threatening myasthenic crises.7 Timely diagnostic confirmation and protocolised therapeutic interventions remain pivotal for optimising long-­ term clinical outcomes in this vulnerable population.8 The conventional therapeutic armamentarium for MG encompasses acetylcholinesterase inhib",
      "score": 0.5746579
    },
    {
      "number": 2,
      "title": "Myasthenia gravis - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/238",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Treatments include the anticholinesterase inhibitor pyridostigmine and immunotherapy (a corticosteroid or other immunosuppressant). Thymectomy is required if thymoma is present. Thymectomy has also been shown to be effective in people with generalized MG without thymoma who are AChR antibody positiv",
      "score": 0.49392182
    },
    {
      "number": 3,
      "title": "Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature | Journal for ImmunoTherapy of Cancer",
      "detail": "jitc.bmj.com",
      "url": "https://jitc.bmj.com/content/7/1/319",
      "authors": "jitc.bmj.com",
      "host": "jitc.bmj.com",
      "snippet": "a second-line use of IVIG or PLEX. In contrast to our findings, the clinical practice guidelines for management of ICI-related MG recommend adding IVIG or PLEX if patients had no improvement/worsening on steroid alone, or presented with severe symptoms (MGFA class III to V) [38][39]. Given the acute",
      "score": 0.4286405
    },
    {
      "number": 4,
      "title": "Predictors of Extubation Failure in Myasthenic Crisis",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/795877",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "Myasthenic crisis (MC) is defined by the development of neuromuscular respiratory failure from myasthenia gravis that requires mechanical ventilation or endotracheal intubation for airway protection.1 Approximately 8% to 27% of patients with myasthenia gravis experience MC,2 and the mortality of pat",
      "score": 0.29474297
    },
    {
      "number": 5,
      "title": "Noninvasive Ventilation in Myasthenic Crisis - JAMA Network",
      "detail": "jamanetwork.com",
      "url": "https://jamanetwork.com/journals/jamaneurology/fullarticle/795076",
      "authors": "jamanetwork.com",
      "host": "jamanetwork.com",
      "snippet": "Immunotherapy was administered in all cases, including plasma exchange in 40 episodes (67%), high-dose intravenous corticosteroids in 13 episodes (22%), and",
      "score": 0.52700067
    },
    {
      "number": 6,
      "title": "Intravenous immunoglobulins may prevent prednisone-exacerbation in myasthenia gravis | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-020-70539-4",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "and shortened hospital stays29.\"). The European Federation of the Neurological Societies recommends using IVIG to treat exacerbations or for maintenance in some cases of refractory MG30.\"). Currently there is class A evidence to use IVIG to treat exacerbations of MG31.\"). In addition, some authors r",
      "score": 0.57064295
    },
    {
      "number": 7,
      "title": "Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis | Scientific Reports",
      "detail": "www.nature.com",
      "url": "https://www.nature.com/articles/s41598-024-79918-7",
      "authors": "www.nature.com",
      "host": "www.nature.com",
      "snippet": "Article \nGoogle Scholar\n\nWojciech, S. et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol. Intensive Ther.  (2013).\n\nArticle \nGoogle Scholar\n\nPushpa, N. et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurolo",
      "score": 0.39326903
    },
    {
      "number": 8,
      "title": "Neuromuscular Disorders in the Intensive Care Unit - Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2021/10000/neuromuscular_disorders_in_the_intensive_care_unit.10.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Corticosteroids are an important part of the treatment of a myasthenic crisis and should be used in most patients. Corticosteroids should be administered",
      "score": 0.46832922
    },
    {
      "number": 9,
      "title": "Acute Neuromuscular Respiratory Failure | Continuum",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/continuum/fulltext/2015/10000/acute_neuromuscular_respiratory_failure.9.aspx",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "Prompt initiation of immunomodulatory therapy with plasma exchange or IVIg is effective in patients with GBS and myasthenic crisis, and these patients can",
      "score": 0.46337196
    },
    {
      "number": 10,
      "title": "Risk factors of myasthenic crisis after thymectomy for thymoma ...",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ejcts/article/52/4/692/4036297",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "The Myasthenia Gravis Foundation of America (MGFA) classification ... respiratory failure. Other major complications included phrenic nerve",
      "score": 0.5462305
    },
    {
      "number": 11,
      "title": "Myasthenic crisis",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27832",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "1 Bedlack and Sanders initially proposed that MC be defined as a clinical scenario of severe > Abbreviations: AChR, acetylcholine receptor; ADL, activity of daily living; ARDS, acute respiratory distress syndrome; FcRn, neonatal Fc receptor; HFNC, high-flow nasal cannula; ICU, intensive care unit; I",
      "score": 0.42978892
    },
    {
      "number": 12,
      "title": "Thymectomy for non-thymomatous myasthenia gravis",
      "detail": "academic.oup.com",
      "url": "https://academic.oup.com/ejcts/article-pdf/37/1/7/17791644/37-1-7.pdf",
      "authors": "academic.oup.com",
      "host": "academic.oup.com",
      "snippet": "In the trans-sternal thymectomy group, one patient was classified as MGFA class V and had MG crisis and respiratory failure before the surgery.",
      "score": 0.41634628
    },
    {
      "number": 13,
      "title": "Myasthenic crisis: Guidelines for prevention and treatment",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S0022510X07003127",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "a high dose initiation therapy is recommended. Either PE or IVIG therapy to avoid severe exacerbation related to therapy should support this. A",
      "score": 0.51618147
    },
    {
      "number": 14,
      "title": "Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/pii/S030384672500294X",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "Title: Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how - ScienceDirect\n## Clinical Neurology and Neurosurgery. Volume 256, September 2025, 109011. # Review Article Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and ho",
      "score": 0.51091194
    },
    {
      "number": 15,
      "title": "Myasthenic crisis: Guidelines for prevention and treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0022510X07003127",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### Neurology\n\n### Intravenous immunoglobulin for myasthenia gravis\n\n### Cochrane Database Syst Rev\n\n### Therapy of myasthenic crisis\n\n### Crit Care Med\n\n### The effect of use of pyridostigmine and requirement of vercuronium in patients with myasthenia gravis\n\n### J Postgrad Med\n\n### Therapy of myas",
      "score": 0.48221022
    },
    {
      "number": 16,
      "title": "Effect of Intravenous Immunoglobulin or Plasmapheresis in Myasthenic Crisis and Worsening Myasthenia Gravis Compared to Without Rescue Treatment - ScienceDirect",
      "detail": "www.sciencedirect.com",
      "url": "https://www.sciencedirect.com/science/article/abs/pii/S0149291825002188",
      "authors": "www.sciencedirect.com",
      "host": "www.sciencedirect.com",
      "snippet": "### J Neuromuscul Dis\n\n### The myasthenic patient in crisis: an update of the management in Neurointensive Care Unit\n\n### Arq Neuropsiquiatr\n\n### Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry\n\n### Eur J Neurol\n\n### Getting rid of weakness in the I",
      "score": 0.46672463
    },
    {
      "number": 17,
      "title": "Myasthenic crisis - Claytor - 2023 - Muscle & Nerve",
      "detail": "onlinelibrary.wiley.com",
      "url": "https://onlinelibrary.wiley.com/doi/full/10.1002/mus.27832",
      "authors": "onlinelibrary.wiley.com",
      "host": "onlinelibrary.wiley.com",
      "snippet": "We recommend three plasmapheresis treatments in patients who need preoperative optimization. NIV may also be helpful for avoiding re-intubation",
      "score": 0.33469868
    },
    {
      "number": 18,
      "title": "1670: COMPARATIVE EFFICACY OF IVIG AND PLASMA... - Lippincott",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/ccmjournal/fulltext/10.1097/01.ccm.0001188676.64318.06~1670-comparative-efficacy-of-ivig-and-plasma-exchange-in",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "IVIG showed lower mortality in myasthenia crisis, but length of intubation and length of hospital stay were comparable between IVIG and plasma exchange.",
      "score": 0.68874115
    },
    {
      "number": 19,
      "title": "Myasthenic crisis : Muscle & Nerve - Ovid",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/01445484-202307000-00006",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "plasmapheresis and IVIG are comparable in terms of efficacy, several studies have suggested that plasmapheresis led to faster and more noticeable clinical",
      "score": 0.62934244
    },
    {
      "number": 20,
      "title": "International consensus guidance for management of myasthenia gravis",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000002790",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "2. PLEX and IVIg are used as short-term treatment for impending and manifest myasthenic crisis and in patients with significant respiratory or bulbar dysfunction. Corticosteroids or other IS agents are often started at the same time to achieve a sustained clinical response. (Because corticosteroids ",
      "score": 0.7159213
    },
    {
      "number": 21,
      "title": "3 Committee discussion | Rozanolixizumab for treating antibody-positive generalised myasthenia gravis | Guidance | NICE",
      "detail": "www.nice.org.uk",
      "url": "https://www.nice.org.uk/guidance/ta1155/chapter/3-Committee-discussion",
      "authors": "www.nice.org.uk",
      "host": "www.nice.org.uk",
      "snippet": "they would expect people to try IVIg or PLEX unless the condition did not respond to either of these. The clinical experts also noted that they expect the use of PLEX to increase, and the use of standard care only (corticosteroids or NSIST) to decrease in the future, citing the 2025 ABN guidelines. ",
      "score": 0.6453216
    },
    {
      "number": 22,
      "title": "International consensus guidance for management of myasthenia ...",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/pdfdirect/10.1212/wnl.0000000000002790",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "IV immunoglobulin (IVIg) and plasma exchange. (PLEX). 3. Impending and ... PLEX and IVIg are the mainstay of management in myasthenic crisis.",
      "score": 0.6133529
    },
    {
      "number": 23,
      "title": "Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/WNL.0000000000010651",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "As discussed earlier, in most instances it may be more appropriate to use IVIg instead of PLEX in the setting of myasthenia and COVID-19 infection. One particular concern is that PLEX indiscriminately removes both harmful and protective antibodies.3 Of note, while the serologic response to COVID-19 ",
      "score": 0.54492307
    },
    {
      "number": 24,
      "title": "Myasthenia gravis",
      "detail": "www.neurology.org",
      "url": "https://www.neurology.org/doi/10.1212/CPJ.0b013e31828d9fec",
      "authors": "www.neurology.org",
      "host": "www.neurology.org",
      "snippet": "Crossref\n\nPubMed\n\nGoogle Scholar\n\n4.\n\nBenatar M, Sanders DB, Burns TM, et al. Recommendations for myasthenia gravis clinical trials. _Muscle Nerve_ 2012;_45_:909–917.\n\nCrossref\n\nPubMed\n\nGoogle Scholar\n\n5.\n\nQureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin tr",
      "score": 0.49963441
    }
  ],
  "publishedAt": "2026-09-15T21:20:37.927807+00:00",
  "updatedAt": "2026-09-15T21:20:37.927807+00:00",
  "readingMinutes": 7,
  "slug": "myasthenic-crisis-treatment-selection"
}